Intelligence / Healthtech / PMA Approvals / Balt USA, LLC
Approvalsdevice change approved (PMA)16 Oct 2026
Balt USA, LLC
16 Oct 2026: Device change approved (PMA) · SQUID Liquid Embolic Agent (LEA). Recorded in the openFDA device PMA data.
- Decided
- 16 Oct 2026
- Device
- SQUID Liquid Embolic Agent (LEA)
- Specialty
- Neurology
- Type
- Supplement (Normal 180 Day Track No User Fee)
- Reason
- Postapproval Study Protocol
- Reference
- P250009 S001
- Location
- Irvine, CA
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Balt USA, LLC
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
More in Neurology
PMA Approvals
24 OctStryker Neurovasculardevice change approved (PMA) · Neuroform Atlas® Stent SystemApprovals23 OctCerenovus, INC.device change approved (PMA) · TRUFILL n-BCA Liquid Embolic SystemApprovals15 OctBoston Scientific Corpdevice change approved (PMA) · Vercise DBS SystemsApprovals14 OctEv3 Neurovasculardevice change approved (PMA) · Onyx Liquid Embolic System (Onyx LES)Approvals1 OctPramand, LLCdevice change approved (PMA) · CraniSeal Dural SealantApprovals18 SeptNovocure, GMBHdevice change approved (PMA) · Novocure GmbHs Optune GioApprovals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.